
Exploring Two Distinct Residential Choices in Singapore
Choosing a home is more than just selecting a property; it is about finding a lifestyle that aligns with your values, preferences, and future goals. In Singapore's dynamic real estate market, Skye At Holland and Tengah Gardens Residences offer two contrasting living experiences that cater to different lifestyles. Skye At Holland is synonymous with urban luxury in a prestigious district, while Tengah Gardens embodies green living and sustainability in a fresh, evolving township. This article compares these developments to help you determine which suits your lifestyle best.
Skye At Holland is situated in District 10, an established and highly sought-after residential area known for its upscale vibe and proximity to Singapore's city core. Nestled near Holland Village, it offers residents seamless access to vibrant nightlife, trendy eateries, shopping, and cultural activities. Connectivity is a strong suit, with Holland Village MRT station nearby and major expressways facilitating easy commutes.
In contrast, Tengah Gardens Residences is located in Tengah, a newly developed township located in the western part of Singapore. Tengah is Singapore's first 'Forest Town,' designed with sustainability at its core. Although it is farther from the central business district, Tengah benefits from upcoming transport infrastructure such as the Jurong Region Line, which promises to enhance accessibility in the near future. This location appeals to those who prioritize tranquility and natural surroundings over immediate city convenience.
Tengah, touted as Singapore's first smart and sustainable town, represents a bold vision for the future of urban living. Built on a former military training area, it's designed to be a green and car-lite environment, prioritizing pedestrian and cyclist access.
Residents of Tengah will benefit from a plethora of new facilities and amenities, built from the ground up with sustainability in mind. Key highlights include: A Central Park as its Core: A sprawling Central Park will serve as the town's green lung, offering residents ample opportunities for recreation and connection with nature.
Smart Solutions: With a focus on smart technologies, Tengah aims to optimize energy consumption, waste management, and traffic flow, contributing to a more efficient and sustainable lifestyle.
The architectural themes of the two developments mirror their lifestyle appeals. Skye At Holland showcases sleek, modern design with attention to luxurious finishes and efficient use of space. The development's boutique scale offers exclusivity, while unit layouts are tailored for singles, couples, and small families who appreciate contemporary urban aesthetics and comfort.Tengah Gardens Residences, meanwhile, embraces architecture that integrates seamlessly with its verdant environment. Emphasizing eco-friendly materials and designs that maximize natural light and ventilation, the residences promote a healthy living atmosphere. Units are generally larger to accommodate families, with open layouts that encourage interaction with nature, both inside and out.
In contrast to Tengah's Greenfield development, Holland Village is undergoing a carefully considered urban transformation that respects its rich history and vibrant character. While maintaining its bohemian charm, Holland Village is poised to evolve into a dynamic hub for innovation and collaboration.
A key element of this transformation is the development of the Dover Innovation District (DID), a new precinct adjacent to Holland Village. The DID aims to foster collaboration between startups, researchers, and established companies, creating a thriving ecosystem for innovation and technology.
Skye At Holland offers upscale amenities typical of luxury city living, including a rooftop pool, fitness center, and landscaped gardens that provide urban retreats within the city. The condo's location means residents have easy access to Holland Village's restaurants, bars, and shopping, which complements the private facilities within the development.Conversely, Tengah Gardens focuses on amenities that support an eco-conscious lifestyle. Residents enjoy extensive green spaces, cycling and jogging paths, community gardens, and outdoor fitness stations. The town's design encourages walking and social interaction, fostering a close-knit community bonded by shared environmental values. Sustainability features such as rainwater harvesting and solar panels are integrated into daily living, enhancing the green experience.
Environmental consciousness is a core strength of Tengah Gardens Residences. As part of Singapore's green town initiative, Tengah is designed to minimize ecological impact, incorporating smart energy solutions, waste reduction programs, and biodiversity conservation efforts. The town promotes sustainable living practices at every level, making it a pioneer in environmentally responsible urban development.Skye At Holland, while primarily focused on luxury, does integrate some green features such as energy-efficient lighting and garden spaces. However, the urban location and boutique scale limit the extent to which it can fully embrace sustainability compared to Tengah's comprehensive green town concept. For buyers prioritizing an environmentally responsible lifestyle, Tengah offers a more immersive experience.
Skye At Holland appeals mainly to urban professionals, expatriates, and small families who seek convenience, exclusivity, and sophisticated living in the city's core. Its proximity to work, social hotspots, and reputable schools makes it attractive to those who value a cosmopolitan lifestyle.Tengah Gardens Residences is geared more toward families, environmentally minded buyers, and those looking to balance modern living with nature. Its spacious units and family-friendly design appeal to those who prioritize wellness and community. As Tengah matures, it will also attract individuals who value long-term investment in an innovative township.
From an investment perspective, Skye At Holland benefits from its location in an established, prestigious district with consistent demand for luxury properties. Its boutique nature and limited supply contribute to stable capital appreciation and strong rental yields, making it a relatively low-risk option for investors.Tengah Gardens Residences offers potential for significant growth as the township develops. Early buyers may benefit from rising property values as infrastructure and community facilities expand. The emphasis on sustainability and smart living also aligns with future market trends, though investors should consider the longer timeline associated with emerging developments.
Skye At Holland currently enjoys excellent connectivity, with immediate access to MRT lines, bus routes, and expressways. This translates to shorter commutes and easy access to the city's amenities, work centers, and entertainment venues—ideal for busy professionals.Tengah Gardens Residences is supported by future infrastructure projects that aim to enhance accessibility, such as the Jurong Region Line MRT and new road networks. Although current connectivity is developing, these planned upgrades are expected to integrate Tengah into Singapore's wider transport system more effectively, attracting residents willing to invest in future convenience.
Both Skye At Holland and Tengah Gardens Residences offer compelling lifestyle choices, each with its unique strengths. Skye At Holland represents the epitome of urban luxury, perfect for those who crave convenience, exclusivity, and the vibrant city life. Tengah Gardens offers a contrasting vision focused on green living, community, and sustainability, ideal for families and individuals seeking a peaceful, nature-centric environment.Choosing the right development ultimately depends on your lifestyle priorities, family needs, and investment outlook. If you value immediate access to city amenities and prefer a cosmopolitan environment, Skye At Holland is an excellent choice. If a sustainable lifestyle, spacious living, and long-term growth in a green township appeal more to you, Tengah Gardens Residences stands out as the better fit. Both developments highlight Singapore's diverse approach to modern living, reflecting the city's dynamic and forward-looking residential landscape.
TIME BUSINESS NEWS

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time Business News
5 days ago
- Time Business News
Exploring Two Distinct Residential Choices in Singapore
Choosing a home is more than just selecting a property; it is about finding a lifestyle that aligns with your values, preferences, and future goals. In Singapore's dynamic real estate market, Skye At Holland and Tengah Gardens Residences offer two contrasting living experiences that cater to different lifestyles. Skye At Holland is synonymous with urban luxury in a prestigious district, while Tengah Gardens embodies green living and sustainability in a fresh, evolving township. This article compares these developments to help you determine which suits your lifestyle best. Skye At Holland is situated in District 10, an established and highly sought-after residential area known for its upscale vibe and proximity to Singapore's city core. Nestled near Holland Village, it offers residents seamless access to vibrant nightlife, trendy eateries, shopping, and cultural activities. Connectivity is a strong suit, with Holland Village MRT station nearby and major expressways facilitating easy commutes. In contrast, Tengah Gardens Residences is located in Tengah, a newly developed township located in the western part of Singapore. Tengah is Singapore's first 'Forest Town,' designed with sustainability at its core. Although it is farther from the central business district, Tengah benefits from upcoming transport infrastructure such as the Jurong Region Line, which promises to enhance accessibility in the near future. This location appeals to those who prioritize tranquility and natural surroundings over immediate city convenience. Tengah, touted as Singapore's first smart and sustainable town, represents a bold vision for the future of urban living. Built on a former military training area, it's designed to be a green and car-lite environment, prioritizing pedestrian and cyclist access. Residents of Tengah will benefit from a plethora of new facilities and amenities, built from the ground up with sustainability in mind. Key highlights include: A Central Park as its Core: A sprawling Central Park will serve as the town's green lung, offering residents ample opportunities for recreation and connection with nature. Smart Solutions: With a focus on smart technologies, Tengah aims to optimize energy consumption, waste management, and traffic flow, contributing to a more efficient and sustainable lifestyle. The architectural themes of the two developments mirror their lifestyle appeals. Skye At Holland showcases sleek, modern design with attention to luxurious finishes and efficient use of space. The development's boutique scale offers exclusivity, while unit layouts are tailored for singles, couples, and small families who appreciate contemporary urban aesthetics and Gardens Residences, meanwhile, embraces architecture that integrates seamlessly with its verdant environment. Emphasizing eco-friendly materials and designs that maximize natural light and ventilation, the residences promote a healthy living atmosphere. Units are generally larger to accommodate families, with open layouts that encourage interaction with nature, both inside and out. In contrast to Tengah's Greenfield development, Holland Village is undergoing a carefully considered urban transformation that respects its rich history and vibrant character. While maintaining its bohemian charm, Holland Village is poised to evolve into a dynamic hub for innovation and collaboration. A key element of this transformation is the development of the Dover Innovation District (DID), a new precinct adjacent to Holland Village. The DID aims to foster collaboration between startups, researchers, and established companies, creating a thriving ecosystem for innovation and technology. Skye At Holland offers upscale amenities typical of luxury city living, including a rooftop pool, fitness center, and landscaped gardens that provide urban retreats within the city. The condo's location means residents have easy access to Holland Village's restaurants, bars, and shopping, which complements the private facilities within the Tengah Gardens focuses on amenities that support an eco-conscious lifestyle. Residents enjoy extensive green spaces, cycling and jogging paths, community gardens, and outdoor fitness stations. The town's design encourages walking and social interaction, fostering a close-knit community bonded by shared environmental values. Sustainability features such as rainwater harvesting and solar panels are integrated into daily living, enhancing the green experience. Environmental consciousness is a core strength of Tengah Gardens Residences. As part of Singapore's green town initiative, Tengah is designed to minimize ecological impact, incorporating smart energy solutions, waste reduction programs, and biodiversity conservation efforts. The town promotes sustainable living practices at every level, making it a pioneer in environmentally responsible urban At Holland, while primarily focused on luxury, does integrate some green features such as energy-efficient lighting and garden spaces. However, the urban location and boutique scale limit the extent to which it can fully embrace sustainability compared to Tengah's comprehensive green town concept. For buyers prioritizing an environmentally responsible lifestyle, Tengah offers a more immersive experience. Skye At Holland appeals mainly to urban professionals, expatriates, and small families who seek convenience, exclusivity, and sophisticated living in the city's core. Its proximity to work, social hotspots, and reputable schools makes it attractive to those who value a cosmopolitan Gardens Residences is geared more toward families, environmentally minded buyers, and those looking to balance modern living with nature. Its spacious units and family-friendly design appeal to those who prioritize wellness and community. As Tengah matures, it will also attract individuals who value long-term investment in an innovative township. From an investment perspective, Skye At Holland benefits from its location in an established, prestigious district with consistent demand for luxury properties. Its boutique nature and limited supply contribute to stable capital appreciation and strong rental yields, making it a relatively low-risk option for Gardens Residences offers potential for significant growth as the township develops. Early buyers may benefit from rising property values as infrastructure and community facilities expand. The emphasis on sustainability and smart living also aligns with future market trends, though investors should consider the longer timeline associated with emerging developments. Skye At Holland currently enjoys excellent connectivity, with immediate access to MRT lines, bus routes, and expressways. This translates to shorter commutes and easy access to the city's amenities, work centers, and entertainment venues—ideal for busy Gardens Residences is supported by future infrastructure projects that aim to enhance accessibility, such as the Jurong Region Line MRT and new road networks. Although current connectivity is developing, these planned upgrades are expected to integrate Tengah into Singapore's wider transport system more effectively, attracting residents willing to invest in future convenience. Both Skye At Holland and Tengah Gardens Residences offer compelling lifestyle choices, each with its unique strengths. Skye At Holland represents the epitome of urban luxury, perfect for those who crave convenience, exclusivity, and the vibrant city life. Tengah Gardens offers a contrasting vision focused on green living, community, and sustainability, ideal for families and individuals seeking a peaceful, nature-centric the right development ultimately depends on your lifestyle priorities, family needs, and investment outlook. If you value immediate access to city amenities and prefer a cosmopolitan environment, Skye At Holland is an excellent choice. If a sustainable lifestyle, spacious living, and long-term growth in a green township appeal more to you, Tengah Gardens Residences stands out as the better fit. Both developments highlight Singapore's diverse approach to modern living, reflecting the city's dynamic and forward-looking residential landscape. TIME BUSINESS NEWS
Yahoo
22-05-2025
- Yahoo
Skye Bioscience to Participate in Upcoming Investment Conferences
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye'), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming healthcare conferences: Investment Conferences Jefferies Global Healthcare Conference (New York) Presentation Thursday, June 5, 9:20 AM ET + 1x1 meetings Sachs European BioPharma Obesity Innovation Forum Next Gen Therapeutics Panel + presentation + 1x1 meetings, Wednesday, June 11 Available webcasts will be accessible on Skye's website. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial ( NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: Connect with us on X and LinkedIn. CONTACTS Investor Relations ir@ (858) 410-0266 LifeSci Advisors, Mike Moyer mmoyer@ (617) 308-4306 Media Inquiries LifeSci Communications, Michael Fitzhugh mfitzhugh@ (628) 234-3889 FORWARD LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including 'anticipated,' 'plans,' 'goal,' 'focus,' 'aims,' 'intends,' 'believes,' 'can,' 'could,' 'challenge,' 'predictable,' 'will,' 'would,' 'may' or the negative of these terms or other comparable terminology. These forward looking statements include, but are not limited to: (i) statements regarding the superior safety and tolerability profile of nimacimab relative to other small molecule CB1 inhibitors, (ii) statements relating to any expectations regarding the efficacy and therapeutic potential of nimacimab as a monotherapy or in combination with a GLP-1 targeted drug, including expectations based on preclinical DIO models, (iii) statements regarding nimacimab's potential to change weight loss standards of care, (iv) statements regarding superior potency of nimacimab to other small molecule CB1 inhibitors based on nimacimab's mechanism of action and (v) statements regarding the timing of receipt of final data from Skye's Phase 2 obesity study of nimacimab. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company's periodic filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of Skye's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-05-2025
- Yahoo
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity model In vitro data reported from new preclinical study highlights superior potency of peripherally restricted CB1 inhibitor, nimacimab, versus monlunabant when tested under pathological levels of CB1 agonists Expanded preclinical study data to be presented at ADA in June 2025 Top-line data readout from CBeyond™ Phase 2a study of nimacimab expected late Q3/early Q4 2025 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) ('Skye' or the 'Company'), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2025, along with key accomplishments and upcoming milestones. 'In Q1, we made decisive progress across clinical operations and R&D,' said Punit Dhillon, President & CEO of Skye. 'Nimacimab continues to demonstrate a differentiated profile as a potential weight loss therapy, with a peripherally restricted mechanism that may set it apart from both GLP-1s and small-molecule CB1 inhibitors. We're advancing a body of preclinical and clinical evidence that supports its potential in reshaping the treatment landscape in obesity.'Clinical engagement remains strong: Patients continue to receive active treatment and are progressing through scheduled follow-ups, supported by ongoing collaboration between the clinical team and study sites. Safety reviews: Data Safety Monitoring Committee has completed three reviews with no concerns raised. The study continues per protocol. Institutional Review Board ('IRB') approval: The IRB has approved the open-label study extension to 52 weeks. We are finalizing the study protocol with the FDA in preparation for data: Preclinical data further demonstrated the potential efficacy and potency of nimacimab. Enhanced safety: Diet-induced obesity ('DIO') mouse model data highlighted the sufficiency of the highly-peripherally restricted CB1 inhibitor nimacimab--without central (brain) exposure--to drive weight loss, with similar efficacy compared to the less-peripherally restricted CB1 inhibitor monlunabant, which may be challenged by brain exposure and the risk of neuropsychiatric side effects. Nimacimab combined with the dual GLP-1/GIP agonist tirzepatide achieved over 30% weight loss Nimacimab alone produced 23.5% weight loss, comparable to monlunabant and tirzepatide alone in this study. Superior potency: In vitro nimacimab's differentiated and favorable mechanism of CB1 inhibition showed superior potency versus the small molecule CB1 inhibitor monlunabant under the elevated concentrations of CB1 agonist associated with obesity. First Quarter 2025 Financial Results:Cash and cash equivalents and short-term investments totaled $59.2 million as of March 31, 2025. The Company expects its current capital to fund projected operations and key clinical milestones through at least Q1 2027, which includes the completion of its extended Phase 2a study for nimacimab and Phase 2b manufacturing but excluding the Phase 2b clinical study and manufacturing activities necessary to supply later stage studies.R&D Expenses:Research and development (R&D) expenses for the three months ended March 31, 2025, were $7.2 million, as compared to $1.9 million for the same period in 2024. The increase was primarily due to contract manufacturing and clinical trial costs associated with our Phase 2a clinical study for nimacimab, salaries and stock based compensation, consulting and depreciation expense. G&A Expenses:General and administrative (G&A) expenses for the three months ended March 31, 2025, were $4.6 million, as compared to $4.2 million for the same period in 2024. The increase was primarily related to investor relations, marketing and communication costs and consulting and advisory fees. Net Loss:Net loss for the three months ended March 31, 2025, totaled $11.1 million, with non-cash share-based compensation expense of $2.2 million, compared to $5.0 million for the same period in 2024, with non-cash share-based compensation expense of $2.5 million. Conference Call Details Skye will host a conference call to discuss its Q1 2025 results at 1:30 p.m. PT/4:30 p.m. ET today, May 8, 2025. The live streaming of the call can be accessed at the Skye Investor Relations website, along with the Company's earnings press release, financial tables, and investor presentation. Following the call, a replay and transcript will be available at the same website. ABOUT SKYE BIOSCIENCE Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial ( NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: Connect with us on X and LinkedIn. FORWARD LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including 'anticipated,' 'plans,' 'goal,' 'focus,' 'aims,' 'intends,' 'believes,' 'can,' 'could,' 'challenge,' 'predictable,' 'will,' 'would,' 'may' or the negative of these terms or other comparable terminology. These forward looking statements include, but are not limited to: (i) statements regarding the superior safety and tolerability profile of nimacimab relative to other small molecule CB1 inhibitors, (ii) statements relating to any expectations regarding the efficacy and therapeutic potential of nimacimab as a monotherapy or in combination with a GLP-1 targeted drug, including expectations based on preclinical DIO models, (iii) statements regarding nimacimab's potential to change weight loss standards of care, (iv) statements regarding superior potency of nimacimab to other small molecule CB1 inhibitors, such as monlunabant, based on nimacimab's mechanism of action (v) statements regarding the timing of receipt of topline data from Skye's Phase 2 obesity study of nimacimab and (vi) statements regarding the timing of enrollment for the 52-week enrollment study. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company's periodic filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of Skye's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements. SKYE BIOSCIENCE, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months EndedMarch 31, 2025 2024 Operating expenses Research and development $ 7,197,257 $ 1,946,450 General and administrative 4,562,305 4,205,800 Total operating expenses 11,759,562 6,152,250 Operating loss (11,759,562 ) (6,152,250 ) Other expense (income) Interest expense 1,452 436,936 Interest income (619,054 ) (427,554 ) Gain on sale of asset — (1,145,141 ) Other (income) expense (40,641 ) 1,040 Total other (income) expense, net (658,243 ) (1,134,719 ) Loss before income taxes (11,101,319 ) (5,017,531 ) Provision for income taxes 2,000 2,000 Net loss $ (11,103,319 ) $ (5,019,531 ) Loss per common share: Basic $ (0.28 ) $ (0.18 ) Diluted $ (0.28 ) $ (0.18 ) Weighted average shares of common stock outstanding used to compute loss per share: Basic 39,651,888 27,999,901 Diluted 39,651,888 27,999,901 SKYE BIOSCIENCE, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS March 31,2025 December 31,2024 (Unaudited) ASSETS Current assets Cash and cash equivalents $ 46,421,299 $ 68,415,741 Short-term investments 12,802,650 — Prepaid expenses 575,382 201,962 Other current assets 3,228,450 2,209,544 Total current assets 63,027,781 70,827,247 Property and equipment, net 1,304,148 1,432,752 Operating lease right-of-use asset 407,401 449,864 Other assets 53,910 53,910 Total assets $ 64,793,240 $ 72,763,773 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 1,713,832 $ 569,252 Accrued payroll liabilities 656,131 1,114,255 Other current liabilities 847,849 654,201 Estimate for accrued legal contingencies and related expenses 1,913,003 1,818,751 Operating lease liability, current portion 188,645 182,428 Total current liabilities 5,319,460 4,338,887 Non-current liabilities Operating lease liability, net of current portion 223,466 273,162 Total liabilities 5,542,926 4,612,049 Commitments and contingencies Stockholders' equity Preferred stock, $0.001 par value; 200,000 shares authorized at March 31, 2025 and December 31, 2024; no shares issued and outstanding at March 31, 2025 and December 31, 2024 — — Common stock, $0.001 par value; 100,000,000 shares authorized at March 31, 2025 and December 31, 2024; 30,974,559 and 30,974,559 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively 30,975 30,975 Additional paid-in-capital 201,272,330 199,070,421 Accumulated deficit (142,052,991 ) (130,949,672 ) Total stockholders' equity 59,250,314 68,151,724 Total liabilities and stockholders' equity $ 64,793,240 $ 72,763,773 CONTACTS Investor Relationsir@ 410-0266 LifeSci Advisors, Mike Moyermmoyer@ 308-4306 Media Inquiries LifeSci Communications, Michael Fitzhughmfitzhugh@ 234-3889Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data